Research in the last five years has uncovered the presence of specific mutations in the isocitrate dehydrogenase1 (IDH1, R132H at the active site) in >70% of low to mid-grade gliomas, providing a new impetus for drug discovery [171,172]. The gene discussed is IDH1; the disease is glioma.